OCGN ▲ +0.8% - Ocugen, Inc. $OCGN - Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Ocugen rose 0.8% following its announcement that the first patient has been dosed in a Phase 3 registrational trial of OCU410, a modifier gene therapy candidate for geographic atrophy secondary to dry age-related macular degeneration. The advancement of a lead pipeline asset into late-stage clinical testing represents a key milestone for the ophthalmology-focused biotech company. 01-SEP-2026 07:02 AM ET